Biotechnological process for preparing hydroxylated ML-236B derivatives, known as M-4 and M-4′, and analogues thereof
AssigneeLEK Pharmaceuticals and Chemical Company D.D.
InventorsSa{haeck over (s)}o Kranjc, Irena Ivanc, Manica Schauer
Life of this patent
Estimating the term…
Abstract
The very effective conversion of ML-236B substances and derivatives thereof into 6′-hydroxylated products with the microorganisms of species Amycolatopsis orientalis, or with an extract or a hydroxylation-effective enzyme derived from said microorganism, is described. The products obtained are suitable as HMG-CoA reductase inhibitors or intermediates thereof. Thus, the products can be used, for example, as an antihypercholesterolemic in pharmacy.
Claims12
A process for preparing a compound defined by the following formula (I)
- wherein R1 represents substituted or unsubstituted alkyl or substituted or unsubstituted aryl, and R2 independently represents H, substituted or unsubstituted alkyl or a cation;
- or the corresponding lactone (II)
- wherein R1 is as defined above;
- which process comprises contacting a 6′-H analogue of the above formula (I) or (II) for hydroxylation with a microorganism of the species Amycolatopsis orientalis.
A process for preparing and subsequently therapeutically administering HMG-CoA inhibitors defined by the following formula (I)
- wherein R1 represents substituted or unsubstituted alkyl or substituted or unsubstituted aryl, and R2 independently represents H, substituted or unsubstituted alkyl or a cation;
- or the corresponding lactone (II)
- wherein R1 is defined above;
- which process comprises contacting a 6′-H analogue of the above formula (I) or (II) for hydroxylation with a microorganism of the species Amycolaptosis orientalis;
- wherein the compound is administered for the prevention and/or treatment of diseases.
Dependencies are inferred from the claim text.